Analyst Gil Blum from Needham maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) and keeping the price target at $23.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Gil Blum’s rating is based on several factors that highlight the potential of Artiva Biotherapeutics, Inc. Despite the early stage of development, the company benefits from minimal exposure to tariffs due to its mostly in-house manufacturing processes. This strategic approach reduces potential financial risks associated with external economic pressures.
Additionally, while recent regulatory changes at the Center for Biologics Evaluation and Research (CBER) are not seen as favorable, the appointment of Nicole Verdun is viewed positively, indicating continued regulatory support. These elements combined suggest a promising outlook for Artiva, supporting the Buy rating.
In another report released on March 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.